sam537

5 ms·

1.
by sam537 8mo ago
I have completely lost track of what I have read and my thoughts. I really should journal. That being said as somebody else mentioned this is very pleasing to the eye. The UI with no ads and no buy buttons is so refreshing. I see that some
2.
by sam537 1y ago
I came to say this. Free episode to listen to. If you are interested in this it is Nx more cost-effective to listen to Liemandt than to read the adjective laden article.
3.
by sam537 2y ago
Popular and incompletely understood. That analogy is unhelpful to understand processes. It's attempting to explain a incompletely understood phenomenon with another. As someone else said below, the problem of the genome being the &#x2
4.
by sam537 2y ago
You should check out a currently approved drug that is very similar called amivantamab (Rybrevant). Also targets EGFR and MET (MET can sometimes be a resistance mechanism to EGFR blockade).
5.
by sam537 2y ago
The problem here is the potential toxicity of this combination. In lung cancer for example, the combination of anti-EGFR therapy + pembrolizumab led to deadly pneumonitis (lung inflammation). We want to cure more patients, but we don't
6.
by sam537 2y ago
Maybe I can help. Progression is usually defined by radiological endpoints (RECIST 1.1 criteria) meaning that at timepoint x the tumor stayed the same size, got smaller, or grew less than 20%. Radiological measurement is very subjective so
7.
by sam537 2y ago
I am close to some of these institutions and it pains me to hear the trouble you had just getting an answer a yes or no answer or getting your paperwork checked for eligibility. In large institutions there is not only an institutional cultu
8.
by sam537 3y ago
Some comments about dietary science are true. It is extremely impossible to isolate the effect of a single substance (ethically). This person greatly benefited from stopping caffeine intake which is great. It is part of the journey to under
9.
by sam537 3y ago
The text was ok, I do not know anything about spermatogenesis but a fair bit about the JAK/STAT pathway. The abstract was pure LLM, however. It has been retracted.
10.
by sam537 3y ago
Not only that. The JAK "pathway" is complete gibberish. The third figure is a pool of random spheres in "differentiation" steps. The whole Frontiers publishing group is widely seen in academia as worthless, however, sin
11.
by sam537 3y ago
As an animal with similar fastidiousness, I agree. I am happy to have found this. Reminded me of After Dark by Murakami.
12.
by sam537 3y ago
You should also try immunotherapy (pembrolizumab) with chemo if your CPS is >1% before experimental early phase trials.
13.
Why do programming books have animals on the covers?(websitehurdles.com)
4 points by sam537 3y ago|2 comments
14.
by sam537 3y ago
Mildly interesting.
15.
by sam537 3y ago
The lowest of the low? Based on consonant pronunciation? How can you extract a value judgment from how someone speaks?
16.
by sam537 4y ago
This is the bottleneck for one company. We have many companies this size doing the same thing. The issue is large companies (novartis/BMS) sometimes sit on compounds and refuse to develop because they think it may not be worth it, may
17.
by sam537 4y ago
There are a few vaccines that try to 'make' your immune system recognize an abnormal (read cancerous) protein as foreign (Sipleucel T for prostate, GMCSF vaccine for melanoma). Minimal activity.
18.
by sam537 4y ago
Look at GRAIL therapeutics. Cancer sheds DNA that can be detected and amplified. We use this sometimes to try to tell if someone will have a recurrence before scans actually show it. Sequencing is hard, and there are contaminants and diffic
19.
by sam537 4y ago
Oncologist here. You can think of drug development as an extremely wide funnel with a minuscule exit hole. At any given time a medium sized pharmaceutical company has 300-500 drug candidates. From this group 50 make it to phase 1 trials. 4
20.
by sam537 4y ago
The internet can still be a beautiful place.
21.
by sam537 4y ago
I wonder how many of us got sidetracked into playing at work today.
22.
by sam537 4y ago
There are two types PD1 and PDL1 inhibitors. Cancer cells (and our own cells) express PDL1. Our immune cells touch PDL1 with their PD1 and if this connection works then the immune cell does not kill. If the connection does not work (PDL1 or
23.
by sam537 4y ago
This is misleading. Yes, the response rate is extremely high but all of this patients shared a mutation or a group of mutations in mismatch repair proteins (they were all MMR deficient, or mismatch instability high). This effect is shared a
24.
by sam537 5y ago
Thank you.
25.
by sam537 5y ago
It's great to talk in terms of indices and devaluations and of "breaking the bank of England". The lives affected are not even spared an afterthought.
26.
by sam537 5y ago
This just made my day.
27.
by sam537 5y ago
Simplify it like this: T-cell: very effective at killing; not as good at recognizing specific things. Antibodies: not that effective at killing; excellent at specifically recognizing things. CAR-T: Let's stick an antibody against X (eg
28.
by sam537 5y ago
Thank you for sharing this.
29.
by sam537 5y ago
Insta-bookmark. Thank you.
30.
by sam537 5y ago
How does notebook/Jupyter help? What does it add?

More ›